Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Bioprocess™, a first-in-class, off-the-shelf enterprise software solution that makes large-molecule development and CMC activities more efficient and improves process quality. Genedata Bioprocess streamlines and automates complex workflows in cell line development, upstream and downstream process development (USP and DSP) workflows, drug formulation, and analytical development. By supporting the complete large-molecule development workflow, it enables biopharmaceutical, biotechnology, as well as contract manufacturing organizations to more efficiently develop and manufacture novel and generic protein-based therapeutics.
Genedata Bioprocess is the result of long-term collaborations with several biopharmaceutical and biotech partners. The platform will be featured for the first time at the Cell Line Development & Engineering Conference 2016 (Vienna, Austria, April 11-13).
“We are very excited about the first release of Genedata Bioprocess, which automates complex processes in large-molecule development and generates significant efficiencies for our customers,” noted Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Bioprocess, we expand our portfolio of innovative software solutions for biopharma R&D and the biosimilars market. We see a rapidly growing need for fully integrated enterprise platforms that enable our customers to discover, develop, and manufacture biopharmaceuticals in an industrialized and most cost-efficient manner. Genedata is committed to continue investing in innovative software solutions to address these needs.”
Industry’s First Fully Integrated System for Biopharma Process Development
Genedata Bioprocess is the first, fully integrated workflow management platform for biopharma process development that enables automated, high-throughput workflows, and streamlines work in a division-of-labor environment. Its built-in reporting capabilities manage and document all relevant large-molecule CMC activities for any given candidate and handle candidate handover from discovery all the way down to the filing of Biologics License Applications (BLA). The platform can be applied to both antibodies (IgGs, bispecifics, ADCs), antibody mimetics (non-Ig scaffolds), and therapeutic proteins (e.g., engineered FVIII variants, fusion proteins).
Genedata Bioprocess is built on a comprehensive process database with a sophisticated data capture and processing infrastructure. The highly structured database, which incorporates biological domain knowledge, allows for advanced process analytics.
Genedata Bioprocess version 1.0 consists of three application modules, which can be installed and operated individually or in a fully integrated setup:
Genedata Bioprocess is based on an open system architecture, which allows for simple yet flexible integration with various laboratory instruments, including bioreactors, analytical devices, or liquid handling systems, to address customer-specific integration requirements. Its modular architecture meets user-specific requirements, enabling use of the solution throughout the entire development workflow.
More information can be found at www.genedata.com/products/bioprocess/.
To schedule a product demonstration, please email: firstname.lastname@example.org.
Editorial Note: On April 12:50 pm CEST, Genedata Bioprocess will be featured in the Cell Line Development & Engineering Conference —“Genedata BioprocessTM for High Throughput Cell Line Screening & Development” by Christoph Freiberg, Ph.D., Senior Scientific Consultant. To schedule a briefing, contact email@example.com.
Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning platforms, combined with deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, Japan, and the US.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All product and service names mentioned are the trademarks of their respective companies.